Codexis, Inc. (0I0X.L)
USD 5.58
(-2.26%)
USD 5.58
(-2.26%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -76.24 Million USD | -126.96% |
| 2022 | -33.59 Million USD | -57.86% |
| 2021 | -21.27 Million USD | 11.37% |
| 2020 | -24.01 Million USD | -101.17% |
| 2019 | -11.93 Million USD | -9.72% |
| 2018 | -10.87 Million USD | 52.7% |
| 2017 | -22.99 Million USD | -168.71% |
| 2016 | -8.55 Million USD | -12.89% |
| 2015 | -7.58 Million USD | 60.25% |
| 2014 | -19.07 Million USD | 53.83% |
| 2013 | -41.3 Million USD | -33.85% |
| 2012 | -30.85 Million USD | -86.45% |
| 2011 | -16.55 Million USD | -93.77% |
| 2010 | -8.54 Million USD | 57.9% |
| 2009 | -20.28 Million USD | 55.04% |
| 2008 | -45.12 Million USD | -15.78% |
| 2007 | -38.97 Million USD | -108.76% |
| 2006 | -18.67 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -22.75 Million USD | -97.78% |
| 2024 Q3 | -20.64 Million USD | 9.29% |
| 2024 Q1 | -11.5 Million USD | -59.97% |
| 2023 FY | -76.24 Million USD | -126.96% |
| 2023 Q4 | -7.19 Million USD | 79.4% |
| 2023 Q2 | -11.52 Million USD | 49.05% |
| 2023 Q3 | -34.9 Million USD | -202.94% |
| 2023 Q1 | -22.61 Million USD | -79.43% |
| 2022 Q4 | -12.6 Million USD | -26.15% |
| 2022 Q3 | -9.99 Million USD | -278.48% |
| 2022 Q1 | -8.35 Million USD | 18.0% |
| 2022 Q2 | -2.64 Million USD | 68.41% |
| 2022 FY | -33.59 Million USD | -57.86% |
| 2021 Q3 | 2.24 Million USD | 152.61% |
| 2021 Q1 | -9.06 Million USD | -131.33% |
| 2021 Q4 | -10.19 Million USD | -554.1% |
| 2021 FY | -21.27 Million USD | 11.37% |
| 2021 Q2 | -4.26 Million USD | 52.97% |
| 2020 Q4 | -3.92 Million USD | 35.67% |
| 2020 FY | -24.01 Million USD | -101.17% |
| 2020 Q2 | -6.34 Million USD | 17.09% |
| 2020 Q1 | -7.65 Million USD | -1105.04% |
| 2020 Q3 | -6.09 Million USD | 3.94% |
| 2019 Q2 | -6.5 Million USD | -26.69% |
| 2019 Q3 | 343 Thousand USD | 105.27% |
| 2019 FY | -11.93 Million USD | -9.72% |
| 2019 Q1 | -5.13 Million USD | -1014.1% |
| 2019 Q4 | -635 Thousand USD | -285.13% |
| 2018 Q1 | -4.69 Million USD | -583.92% |
| 2018 Q4 | -461 Thousand USD | 76.81% |
| 2018 FY | -10.87 Million USD | 52.7% |
| 2018 Q3 | -1.98 Million USD | 46.77% |
| 2018 Q2 | -3.73 Million USD | 20.43% |
| 2017 Q1 | -7.46 Million USD | -41.83% |
| 2017 Q3 | -10.22 Million USD | -62.83% |
| 2017 Q2 | -6.28 Million USD | 15.82% |
| 2017 FY | -22.99 Million USD | -168.71% |
| 2017 Q4 | 970 Thousand USD | 109.49% |
| 2016 Q3 | 1.43 Million USD | -35.82% |
| 2016 FY | -8.55 Million USD | -12.89% |
| 2016 Q4 | -5.26 Million USD | -466.04% |
| 2016 Q2 | 2.23 Million USD | 132.1% |
| 2016 Q1 | -6.97 Million USD | -239.7% |
| 2015 FY | -7.58 Million USD | 60.25% |
| 2015 Q2 | -5.36 Million USD | 3.63% |
| 2015 Q1 | -5.56 Million USD | -1712.17% |
| 2015 Q3 | 5.39 Million USD | 200.63% |
| 2015 Q4 | -2.05 Million USD | -138.06% |
| 2014 Q1 | -6.37 Million USD | 35.04% |
| 2014 Q2 | -8.47 Million USD | -33.0% |
| 2014 Q3 | -4.56 Million USD | 46.2% |
| 2014 Q4 | 345 Thousand USD | 107.56% |
| 2014 FY | -19.07 Million USD | 53.83% |
| 2013 Q1 | -9.62 Million USD | 38.07% |
| 2013 Q2 | -12.6 Million USD | -30.99% |
| 2013 Q3 | -9.26 Million USD | 26.52% |
| 2013 Q4 | -9.81 Million USD | -5.95% |
| 2013 FY | -41.3 Million USD | -33.85% |
| 2012 Q4 | -15.53 Million USD | -572.93% |
| 2012 FY | -30.85 Million USD | -86.45% |
| 2012 Q1 | -7.49 Million USD | -41.43% |
| 2012 Q3 | -2.3 Million USD | 58.16% |
| 2012 Q2 | -5.51 Million USD | 26.32% |
| 2011 Q1 | -3.47 Million USD | -602.63% |
| 2011 Q2 | -5.04 Million USD | -45.2% |
| 2011 Q3 | -2.74 Million USD | 45.6% |
| 2011 Q4 | -5.29 Million USD | -93.14% |
| 2011 FY | -16.55 Million USD | -93.77% |
| 2010 Q3 | -2.73 Million USD | 30.77% |
| 2010 Q1 | -1.36 Million USD | 73.57% |
| 2010 Q4 | -494 Thousand USD | 81.92% |
| 2010 FY | -8.54 Million USD | 57.9% |
| 2010 Q2 | -3.94 Million USD | -188.24% |
| 2009 FY | -20.28 Million USD | 55.04% |
| 2009 Q1 | -6.09 Million USD | 3.7% |
| 2009 Q4 | -5.18 Million USD | 15.88% |
| 2009 Q3 | -6.15 Million USD | -115.47% |
| 2009 Q2 | -2.85 Million USD | 53.09% |
| 2008 Q4 | -6.32 Million USD | 0.0% |
| 2008 FY | -45.12 Million USD | -15.78% |
| 2008 Q1 | -13.9 Million USD | 0.0% |
| 2007 Q1 | -5.09 Million USD | 0.0% |
| 2007 FY | -38.97 Million USD | -108.76% |
| 2006 FY | -18.67 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Xeris Biopharma Holdings, Inc. | -62.25 Million USD | -22.464% |
| Arrowhead Pharmaceuticals, Inc. | -205.27 Million USD | 62.86% |
| Viridian Therapeutics, Inc. | -237.73 Million USD | 67.931% |
| Organovo Holdings, Inc. | -14.67 Million USD | -419.665% |